Background Severe hypersensitivity reaction is a dangerous adverse drug reaction in
patients receiving cetuximab. It requires drug discontinuation and medical management …

Desensitization therapy can help overcome severe hypersensitivity reactions and allow
continuing administration of the culprit agents. However, this is time-consuming and labor …

Hypersensitivity reactions are a classic side effect of cetuximab. We report the cases of three
patients who developed life-threatening hypersensitivity to cetuximab, which could have …

Objectives. Previous research has indicated a high incidence of cetuximab hypersensitivity
reactions in the southern US. This study documents the incidence of hypersensitivity …

Introduction: Cetuximab is a chimeric mouse-human (30: 70) IgG1 monoclonal antibody that
competitively inhibits the binding of epidermal growth factor. Cetuximab is generally well …

Introduction Cetuximab is a chimeric antibody registered for the therapy of advanced
colorectal carcinoma after failure of standard chemotherapy. Rare infusion reactions that …

Purpose The primary purpose of this study was to determine the rate of infusion reactions to
cetuximab in oncology patients treated at the University of North Carolina Cancer Hospital …

Introduction Cetuximab, an IgG1 monoclonal antibody, is utilized in the treatment of
metastatic colorectal cancer and squamous cell head and neck cancers. Due to the risk of …

In Journal of Clinical Oncology, Tronconi et al1 report a fatal hypersensitivity reaction to
cetuximab in a 63-year-old patient with metastatic colon cancer and outlined a 0.1 …

Discussion Cetuximab is a chimeric anti–epidermal growth factor receptor monoclonal
antibody created by combining the antigen-binding regions of the mouse antibody with the …